ALXN2220 is named as an intervention in 3 current clinical trials in our UK, USA, China and Ireland registers. None are recruiting at the moment. The most common phase is Phase 3. The sponsor with the most trials is Alexion Pharmaceuticals, Inc (2). The most-studied condition is Transthyretin Amyloid Cardiomyopathy (ATTR-CM).
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
NCT07789483 · Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
|
Phase 3 | Not yet open | Alexion Pharmaceuticals, Inc | Ireland, UK, USA, China |
|
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06183931 · ClinicalTrials.gov ↗ · Transthyretin Amyloid Cardiomyopathy
|
Phase 3 | Active, closed | Alexion Pharmaceuticals, Inc | Ireland, UK, USA, China |
|
A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM
NCT07608354 · ClinicalTrials.gov ↗ · Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
|
Phase 2 | Active, closed | AstraZeneca | UK, USA, China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Alexion Pharmaceuticals, Inc | 2 |
| AstraZeneca | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in UK | 3 | 0 |
| Clinical trials in USA | 3 | 0 |
| Clinical trials in China | 3 | 0 |
| Clinical trials in Ireland | 2 | 0 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our UK, USA, China and Ireland registers name ALXN2220 as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 3 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Alexion Pharmaceuticals, Inc (2) and AstraZeneca (1). The number in brackets is how many trials each organisation leads.
Yes. 2 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how ALXN2220 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how ALXN2220 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists ALXN2220 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.